Anti-FLT-1 antibodies in treating duchenne muscular dystrophy

US9957324B2 · kind B2 · utility

Assignees

• SHIRE HUMAN GENETIC THERAPIES, INC. · US
• Regents of the University of Minnesota · US

Inventors

• Serene Josiah · Lexington, US
• Thomas M. Luby · Lexington, US
• Atsushi Asakura · Minneapolis, US
• Dennis Keefe · Smithfield, US
• Lawrence Charnas · Natick, US
• Mayank Verma · Kanchinakote, IN

Key dates

• Filing date: Jan 28, 2014
• Grant date: May 1, 2018
• Expiry date: Jul 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of an anti-Flt-1 antibody, or antigen binding fragment thereof, such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset.